Merck KGaA, Darmstadt, Germany, is collaborating with Iktos, a French start-up company specialized in artificial intelligence (AI) for new drug design, to further accelerate its drug discovery capabilities.
US-based Seres Therapeutics and AstraZeneca have entered into a three-year research collaboration, which will focus on further understanding the potential of microbiome therapeutics in supplementing immuno-oncology treatment.
InventisBio Inc., a clinical stage biotech company, announced the closing of a $70 million USD Series C financing in January 2019.
TaiwanJ Pharmaceuticals has signed a $26 million contract with Newsoara Biopharma to license out its drug candidate JKB-122 for further development in Asia.
Biopharmaceutical firm GTx has entered into a merger agreement with clinical-stage biotechnology firm Oncternal Therapeutics to create a new a publicly-traded and clinical-stage oncology company.
Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, announced the successful completion of a $135m Series B financing.
GeoVax Labs, a biotechnology company developing human vaccines, has expanded its collaboration activities with Leidos, to develop malaria vaccine candidates.
American multinational biotechnology company Biogen has agreed to acquire UK-based clinical-stage gene therapy firm Nightstar Therapeutics in a deal valued at around $877m.
Abpro, a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases, and NJCTTQ, a global pharmaceutical company, have entered into an agreement to develop multiple novel bispecific antibody therapies in immuno-oncology, including best-in -class T-cell engagers.
Third Rock Ventures, a healthcare venture firm focused on disruptive areas of science and medicine, has launched Maze Therapeutics to focus on translating genetic insights into new medicines.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.